Biotest Aktiengesellschaft (BIO.DE)
EUR 41.4
(0.49%)
EUR 41.4
(0.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 179 Million EUR | 628.51% |
| 2022 | 28.3 Million EUR | 210.14% |
| 2021 | -17.7 Million EUR | -226.22% |
| 2020 | 16 Million EUR | -34.92% |
| 2019 | 39.4 Million EUR | -5.26% |
| 2018 | 26 Million EUR | 241.49% |
| 2017 | 3.9 Million EUR | -120.77% |
| 2016 | 53.6 Million EUR | 214.24% |
| 2015 | 62.4 Million EUR | -68.11% |
| 2014 | 82.8 Million EUR | 10.12% |
| 2013 | 82.1 Million EUR | 4.66% |
| 2012 | 73.8 Million EUR | -16.63% |
| 2011 | 75.28 Million EUR | 14.89% |
| 2010 | 81.79 Million EUR | -13.55% |
| 2009 | 88.53 Million EUR | 10.27% |
| 2008 | 85.8 Million EUR | -69.0% |
| 2007 | 55.87 Million EUR | 13.04% |
| 2006 | 44.52 Million EUR | 15.41% |
| 2005 | 40.12 Million EUR | 573.67% |
| 2004 | 31.49 Million EUR | 68.71% |
| 2003 | 18.66 Million EUR | -29.17% |
| 2002 | 26.35 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 54.6 Million EUR | 148.18% |
| 2024 Q2 | 27.3 Million EUR | -50.0% |
| 2023 Q3 | 134.8 Million EUR | 317.34% |
| 2023 Q1 | -5.5 Million EUR | -10.0% |
| 2023 Q2 | 32.3 Million EUR | 687.27% |
| 2023 Q4 | 12.4 Million EUR | -90.8% |
| 2023 FY | - EUR | 628.51% |
| 2022 Q4 | -5 Million EUR | -13.64% |
| 2022 Q3 | -4.4 Million EUR | -266.67% |
| 2022 Q2 | -1.2 Million EUR | -100.0% |
| 2022 Q1 | -600 Thousand EUR | 98.61% |
| 2022 FY | - EUR | 210.14% |
| 2021 FY | - EUR | -226.22% |
| 2021 Q1 | -7.3 Million EUR | 31.13% |
| 2021 Q2 | 3 Million EUR | 141.1% |
| 2021 Q3 | -1.9 Million EUR | -163.33% |
| 2021 Q4 | -43.1 Million EUR | -2168.42% |
| 2020 FY | - EUR | -34.92% |
| 2020 Q1 | 2.8 Million EUR | 149.12% |
| 2020 Q2 | -300 Thousand EUR | -110.71% |
| 2020 Q3 | -5.1 Million EUR | -1600.0% |
| 2020 Q4 | -10.6 Million EUR | -107.84% |
| 2019 Q1 | -7.3 Million EUR | -10.61% |
| 2019 Q3 | -1.1 Million EUR | -114.47% |
| 2019 Q4 | -5.7 Million EUR | -418.18% |
| 2019 FY | - EUR | -5.26% |
| 2019 Q2 | 7.6 Million EUR | 204.11% |
| 2018 Q2 | 8.5 Million EUR | 277.08% |
| 2018 FY | - EUR | 241.49% |
| 2018 Q1 | -4.8 Million EUR | -242.86% |
| 2018 Q3 | 4.7 Million EUR | -44.71% |
| 2018 Q4 | -6.6 Million EUR | -240.43% |
| 2017 Q3 | 4.5 Million EUR | -4.26% |
| 2017 Q2 | 4.7 Million EUR | 118.88% |
| 2017 FY | - EUR | -120.77% |
| 2017 Q4 | -1.4 Million EUR | -131.11% |
| 2017 Q1 | -24.9 Million EUR | -163.2% |
| 2016 Q4 | 39.4 Million EUR | 398.73% |
| 2016 Q2 | 9.6 Million EUR | 11.63% |
| 2016 Q1 | 8.6 Million EUR | -47.24% |
| 2016 FY | - EUR | 214.24% |
| 2016 Q3 | 7.9 Million EUR | -17.71% |
| 2015 FY | - EUR | -68.11% |
| 2015 Q3 | -84.3 Million EUR | -3931.82% |
| 2015 Q4 | 16.3 Million EUR | 119.34% |
| 2015 Q2 | 2.2 Million EUR | 2100.0% |
| 2015 Q1 | 100 Thousand EUR | -99.56% |
| 2014 Q4 | 22.8 Million EUR | 159.09% |
| 2014 FY | - EUR | 10.12% |
| 2014 Q1 | 10.7 Million EUR | -22.46% |
| 2014 Q2 | 15.8 Million EUR | 47.66% |
| 2014 Q3 | 8.8 Million EUR | -44.3% |
| 2013 Q3 | 14 Million EUR | -0.71% |
| 2013 FY | - EUR | 4.66% |
| 2013 Q1 | 11.8 Million EUR | 22.78% |
| 2013 Q2 | 14.1 Million EUR | 19.49% |
| 2013 Q4 | 13.8 Million EUR | -1.43% |
| 2012 Q4 | 9.61 Million EUR | -2.92% |
| 2012 FY | - EUR | -16.63% |
| 2012 Q1 | 10.4 Million EUR | -68.53% |
| 2012 Q2 | 12.5 Million EUR | 20.19% |
| 2012 Q3 | 9.9 Million EUR | -20.8% |
| 2011 FY | - EUR | 14.89% |
| 2011 Q4 | 33.05 Million EUR | 227.24% |
| 2011 Q1 | 9.1 Million EUR | -53.79% |
| 2011 Q3 | 10.1 Million EUR | -7.34% |
| 2011 Q2 | 10.9 Million EUR | 19.78% |
| 2010 Q4 | 19.69 Million EUR | 71.23% |
| 2010 Q3 | 11.5 Million EUR | 0.88% |
| 2010 Q2 | 11.4 Million EUR | -7.32% |
| 2010 FY | - EUR | -13.55% |
| 2010 Q1 | 12.3 Million EUR | -42.44% |
| 2009 Q4 | 21.37 Million EUR | 32.73% |
| 2009 FY | - EUR | 10.27% |
| 2009 Q2 | 16.2 Million EUR | 8.0% |
| 2009 Q1 | 15 Million EUR | 0.0% |
| 2009 Q3 | 16.1 Million EUR | -0.62% |
| 2008 FY | - EUR | -69.0% |
| 2007 FY | - EUR | 13.04% |
| 2006 FY | - EUR | 15.41% |
| 2005 FY | - EUR | 573.67% |
| 2004 FY | - EUR | 68.71% |
| 2003 FY | - EUR | -29.17% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 83.542% |
| CureVac N.V. | -234.09 Million EUR | 176.466% |
| Biotest Aktiengesellschaft | 179 Million EUR | 0.0% |
| BRAIN Biotech AG | -2.38 Million EUR | 7598.953% |
| Formycon AG | 81.05 Million EUR | -120.843% |
| Heidelberg Pharma AG | -18.7 Million EUR | 1056.893% |
| Medigene AG | -14.58 Million EUR | 1327.288% |